FRIDAY DEADLINE: Berger Montague Advises Skye Bioscience, Inc. (NASDAQ: SKYE) Investors to Inquire About a Securities Fraud Class Action by January 16, 2026

Skye, headquartered in San Diego, is a clinical-stage biotechnology company developing treatments for obesity and metabolic diseases. The complaint alleges that, throughout the Class Period, Defendants misled investors as to the prospects of its lead candidate, nimacimab. Investors allegedly learned the truth on October 6, 2025, when Skye published topline findings from its 26- week Phase 2a CBeyond trial of nimacimab, revealing that it failed to meet its primary weight-loss endpoint versus placebo. On this ...